The Satellos advisory board will explore the biology of regeneration, aging and neurodegeneration, the clinical-stage drug developer announced on October 27, 2026. The six-member scientific board will advise the company as it examines questions beyond its existing focus on degenerative muscle diseases.

Key Takeaways

  • The board will advise on stem cell biology, molecular signaling and disease pathology.
  • Janet Rossant, chief of research emeritus at The Hospital for Sick Children, will chair the board.
  • Satellos is evaluating its drug candidate forazapadin in two Phase 2 trials for Duchenne muscular dystrophy.

What the Satellos advisory board will study

The board will examine how aging affects regenerative capacity and how mechanisms governing stem cell behavior may contribute to neurodegenerative disease. Its members bring expertise in stem cell biology, regenerative medicine, neuroscience and small-molecule chemistry.

Chief Scientific Officer Phil Lambert said the board would help the company deepen its understanding of how cellular polarity influences tissue maintenance, regeneration and disease across biological systems.

Who is joining the board

Alongside chair Janet Rossant, the board includes Rima Al-awar of New York University Abu Dhabi; Sebastian Jessberger of the University of Zurich; Mary Mader of MM Molecular Pharma Consulting; Lee Rubin of Harvard University; and Marius Wernig of Stanford University.

Muscle disease trials remain underway

Satellos is developing forazapadin, an orally administered small-molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. The company is evaluating it as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase 2 trials: BASECAMP in pediatric participants and TRAILHEAD in adults.

The U.S. Food and Drug Administration has also cleared an investigational new drug application for clinical evaluation of forazapadin in facioscapulohumeral muscular dystrophy. That clearance is separate from approval of the drug as a treatment.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.